Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Essential Healthcare News.
Press releases published on May 20, 2025
PDS Biotech to Participate at the A.G.P. Virtual Annual Healthcare Company Showcase
GlobeNewswire
·
May 20, 2025
PRINCETON, N.J., May 20, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced …
Bright Minds Biosciences Announces Featured Speakers for its Absence Epilepsy Virtual R&D Day on May 20, 2025
GlobeNewswire
·
May 20, 2025
- Key Opinion Leaders (KOLs) on Absence seizures include Dennis Dlugos, MD, Wendyl D’Souza, MBChB, MPH, FRACP, PhD, and Alexander Rotenberg, MD, PhD - VANCOUVER, British Columbia, May 20, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) ( …
aTyr Pharma to Present at Upcoming Investor Conferences
GlobeNewswire
·
May 20, 2025
SAN DIEGO, May 20, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that …
Marine Biologics Expands Leadership Team to Drive Next Phase of Growth
GlobeNewswire
·
May 20, 2025
BERKELEY, Calif., May 20, 2025 (GLOBE NEWSWIRE) -- Biomaterials company Marine Biologics today introduced Danièle Karleskind, Ph.D. as its new Chief Operations Officer and Ryan Hunt as Director of Business Development. With more than 55 years of combined …
ALX Oncology Highlights Differentiated Design, Preclinical Data and Development Plans for EGFR-Targeted ADC, ALX2004, in R&D Webcast Event
GlobeNewswire
·
May 20, 2025
- A potential best- and first-in-class antibody-drug conjugate (ADC) for the treatment of EGFR-expressing solid tumors, ALX2004 is uniquely designed with every component optimized to maximize the therapeutic window by reducing toxicity - Following recent …
Praxis Precision Medicines to Participate in Upcoming Conferences
GlobeNewswire
·
May 20, 2025
BOSTON, May 20, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by …
Expanded Partnership Increases Access to Unified, Intelligent Radiologist Desktops for Radiology Practices
GlobeNewswire
·
May 20, 2025
TAMPA, Fla. and WAYNE, N.J., May 20, 2025 (GLOBE NEWSWIRE) -- NewVue, a leader in cloud-native radiology workflow solutions, today announced the expansion of its partnership with Konica Minolta Healthcare Americas, Inc. from a referral agreement to a …
Efficacy Results Announced from Cingulate’s Phase 3 Pediatric Study of CTx-1301 (dexmethylphenidate) for ADHD
GlobeNewswire
·
May 20, 2025
Subjects Demonstrated Marked Improvement of ADHD Symptoms at Week 5 New Drug Application on Schedule for this Summer CING CEO Shares Insights and Strategic Outlook on “Unboxing Biotech” Podcast KANSAS CITY, Kan., May 20, 2025 (GLOBE NEWSWIRE) -- Cingulate …
Spectral AI Research Partner Using DeepView System Wins Best Research Project at the 2025 Education Awards
GlobeNewswire
·
May 20, 2025
DALLAS, May 20, 2025 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ: MDAI) (“Spectral AI” or the “Company”), a leading developer of the AI-driven DeepView® System, which uses multi-spectral imaging and AI algorithms to predict burn healing potential today …
Mineralys Therapeutics Announces Late-Breaking Presentation of Phase 3 Launch-HTN Trial at 34th European Meeting on Hypertension and Cardiovascular Protection
GlobeNewswire
·
May 20, 2025
RADNOR, Pa., May 20, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and …
NeurAxis Awarded First Ever FDA Clearance for the Treatment of Pediatric FAP/Functional Dyspepsia (FD) and Associated Nausea Symptoms
GlobeNewswire
·
May 20, 2025
• Significantly expands IB-Stim’s total addressable market • Clearance covers patients aged 8–21 • Seamless go-to-market strategy with existing reimbursement and provider infrastructure CARMEL, Ind., May 20, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“ …
Philikos announces initiation of clinical Phase 1/2 study with T-Guard® in patients with systemic sclerosis
GlobeNewswire
·
May 20, 2025
NIJMEGEN, the Netherlands, May 20, 2025 (GLOBE NEWSWIRE) -- Philikos B.V., a Dutch biotechnology company developing antibody-based therapies to treat severe immune disorders, today announced that it has enrolled the first patient in a Phase 1/2 clinical …
Philikos kondigt de start aan van een klinische fase 1/2-studie met T-Guard® bij patiënten met systemische sclerose
GlobeNewswire
·
May 20, 2025
NIJMEGEN, the Netherlands, May 20, 2025 (GLOBE NEWSWIRE) -- Philikos B.V., een Nederlands biotechnologiebedrijf dat op antilichamen gebaseerde therapieën ontwikkelt voor de behandeling van ernstige immuunziekten, heeft vandaag aangekondigd dat de eerste …
ProPhase Labs Announces Financial Results for the Three Months Ended March 31, 2025
GlobeNewswire
·
May 20, 2025
Highlights Multiple Significant Potential Liquidity Events Anticipated Within the Next Few Months Completes Significant Reductions in Overhead and Expenses BE-Smart Esophageal Cancer Test Study has been Submitted in the Journal of Clinical Gastrointestinal …
Avicanna Announces Sponsorship of Pilot Phase II Clinical Study Osteoarthritis Pain
GlobeNewswire
·
May 20, 2025
TORONTO, May 20, 2025 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based …
Kura Oncology to Participate in Three Upcoming Investor Conferences
GlobeNewswire
·
May 20, 2025
SAN DIEGO, May 20, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that …
Acoramidis Reduced Incidence of Atrial Fibrillation Events in Patients with ATTR-CM
GlobeNewswire
·
May 20, 2025
- In a post-hoc analysis of ATTRibute-CM, acoramidis reduced the annual frequency of CVH due to AF/AFL by 43% compared to placebo and reduced the incidence of new-onset AF/AFL by 17% in the subgroup with no prior history of AF compared to placebo - In the …
Merit Medical Acquires Biolife Delaware, L.L.C.
GlobeNewswire
·
May 20, 2025
Acquired business offers the StatSeal® and WoundSeal® products, which provide hemostasis solutions that complement the wide range of procedures Merit’s portfolio supports. Acquisition projected to add approximately $18 million of revenue, on an annualized …
Quoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Netherton Syndrome
GlobeNewswire
·
May 20, 2025
Company continues to advance QRX003 in late-stage clinical trials in Netherton Syndrome patients Regulatory milestone provides 10 years of market exclusivity in Europe upon approval ASHBURN, Va., May 20, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. …
BriaCell CEO Letter to Shareholders
GlobeNewswire
·
May 20, 2025
Repeated positive recommendation from Data Safety Monitoring Board (“DSMB”) of pivotal Phase 3 study for lead clinical candidate Bria-IMT™ in combination with checkpoint inhibitor Bria-IMT has received Fast Track designation from FDA and patient enrollment …